Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly Gets Breakthrough Therapy Designation for Alzheimer's Treatment From FDA

06/24/2021 | 07:14am EDT

By Dave Sebastian

Eli Lilly & Co. said it has received breakthrough therapy designation for its Alzheimer's treatment from the U.S. Food and Drug Administration.

The designation means preliminary clinical evidence indicates the drug could show substantial improvement over available therapies on a clinically significant endpoint, and is meant to expedite the development and review of drugs for serious conditions, according to the FDA.

Lilly on Thursday said it plans to submit a biologics license application for the drug, donanemab, under the accelerated approval path later this year based on data from its Phase 2 trial. It said the safety, tolerability and efficacy of donanemab are being evaluated in an ongoing Phase 3 study.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

06-24-21 0713ET

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -0.61% 34932.42 Delayed Quote.14.56%
ELI LILLY AND COMPANY 0.07% 243.435 Delayed Quote.44.05%
All news about ELI LILLY AND COMPANY
07/23ELI LILLY AND : (LLY) sees Significant Insider Selling Continuing
MT
07/23A Guiding Light For The Research Safe Harbor And "Research Tools"?
AQ
07/22ELI LILLY AND : Significant Insider Selling Continues at Eli Lilly (LLY)
MT
07/22INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at Eli Lilly
MT
07/22ELI LILLY AND : Lilly Confirms Date and Conference Call for Second-Quarter 2021 ..
PR
07/21INSIDER TRENDS : Selling By Insiders Continues at Eli Lilly
MT
07/19TALKSPACE : Hires Jennifer Fulk as CFO
MT
07/16ELI LILLY AND : Insider Selling in Eli Lilly (LLY) Shares Continues
MT
07/16Health Care Climbs On Defensive Bias -- Health Care Roundup
DJ
07/16ELI LILLY AND : Incyte Say FDA May Miss Target Action Data for Baricitinib
MT
More news
Financials (USD)
Sales 2021 27 273 M - -
Net income 2021 6 550 M - -
Net Debt 2021 11 241 M - -
P/E ratio 2021 33,7x
Yield 2021 1,36%
Capitalization 221 B 221 B -
EV / Sales 2021 8,52x
EV / Sales 2022 8,25x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 243,21 $
Average target price 241,90 $
Spread / Average Target -0,54%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY44.05%221 084
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ABBVIE INC.9.93%208 043